Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Rapid Coronavirus Test Gets FDA Emergency Use Authorization

NEW YORK –BioMérieux said on Tuesday that an assay developed by its subsidiary BioFire Defense to rapidly detect COVID-19, the disease caused by SARS-CoV-2 virus, was granted Emergency Use Authorization by the US Food and Drug Administration.

The BioFire COVID-19 test detects SARS-CoV-2 from nasopharyngeal swabs in transport media in approximately 45 minutes. The test can be run on the BioFire FilmArray system as well as the higher-throughput FilmArray Torch, as previously reported. These platforms require minimal skill and training to operate. They are closed and fully-automated systems that integrate sample preparation, amplification, and detection.

BioMérieux has also received authorization to sell the BioFire COVID-19 test External Control Kit. This positive control material may be used for quality control and laboratory verification of the test, the firm said in a statement.

The BioFire COVID-19 test was developed by leveraging an existing contract between BioFire Defense and the US Department of Defense. It is the second of three tests to be launched by BioMérieux for COVID-19 detection, and the firm said it will also pursue EUA for the two others.

It has already launched a test in France, called SARS-CoV-2 R-Gene, for open real-time PCR platforms, and it is working to expand its FilmArray Respiratory Panel 2 test to include SARS-CoV-2 detection. The new panel will be called FilmArray RP2.1 and will also detect 21 other pathogens that cause respiratory infections.

In addition to the COVID-19 test and respiratory panel, the FilmArray system runs a broad menu of other syndromic multiplex-PCR tests for infectious disease, including pneumonia, bloodstream infections, gastrointestinal infections, meningitis, and encephalitis. BioMérieux said in a recent earnings report that it has placed 10,400 FilmArray instruments to date.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.